| Nymox Pharmaceutical is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia and the treatment of low-grade localized prostate cancer. Co. has developed and markets NicAlert and TobacAlert, which are test strips for determining whether a person is using tobacco products (NicAlert) or has been exposed to second-hand smoke (TobacAlert). Both NicAlert and TobacAlert employ the patented technology of Co.'s subsidiary, Serex, Inc., to provide a read-out of levels of cotinine, a by-product of the body's breakdown of nicotine and generally regarded as the indicator of tobacco exposure for smokers and nonsmokers. We show 15 historical shares outstanding datapoints in our NYMX shares outstanding history coverage, used to compute NYMX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NYMX market cap history over the course of time is important for investors
interested in comparing NYMX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NYMX versus a peer is one thing; comparing
NYMX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NYMX can fluctuate over the course of history.
With this page we aim to empower investors researching NYMX by allowing them to research the NYMX market cap history.